2Strands Biosciences | MedTech Innovator Asia Pacific 2025 | Best Video Competition (Singapore)

Cancer recurrence remains a major cause of mortality, yet current monitoring relies on imaging that detects tumors ≥1 mm, leaving little time to treat aggressive cases. ctDNA blood tests can enable early detection but remain costly and insensitive when ctDNA levels are extremely low post-treatment.

2Strands is developing Recura, an accurate yet affordable ctDNA blood test using proprietary allele-enrichment sequencing to selectively enrich mutant tumor DNA. Recura detects ultra low frequency mutations (LoD 0.001%) at a fraction of the cost (~$500), making ultrasensitive cancer recurrence detection and monitoring accessible beyond elite health systems worldwide.

Funding

Raised till date: USD 308K
USD 20K in equity funding
USD 800K in non-dilutive funding
Seeking (Pre-Seed): USD 1M

Regulatory Status

U.S.
Pathway: LDT
Status: N/A

Development Stage

Prototype Developed – Pre-Clinical